Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.43 |
| ▸ | MAPT | P10636 | 3/20 | 0.43 |
| ▸ | IDO1 | P14902 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.37 |
| ▸ | AR | P10275 | 4/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.37 |
| ▸ | KIF11 | P52732 | 1/20 | 0.37 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 6/20 | 0.35 |
| ▸ | NPC1 | O15118 | 4/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.35 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL70645 | 0.82 | ALDH1A1 (0.42) | LMNAMAPTKDM4EARKMT2A | |
| SCHEMBL468050 | 0.79 | KIF11 (0.50) | KDM4EKMT2AKIF11 | |
| SCHEMBL17626009 | 0.78 | ALDH1A1 (0.40) | MAPTKDM4EKMT2ACYP1A2CYP3A4 | |
| SCHEMBL500232 | 0.78 | RAB9A (0.46) | LMNAMAPTKDM4EARKMT2A | |
| SCHEMBL468044 | 0.78 | RAB9A (0.41) | LMNAMAPTKDM4EKMT2ANOTUM | |
| SCHEMBL10515566 | 0.78 | LTA4H (0.46) | LMNAMAPTKDM4EARKMT2A | |
| SCHEMBL1916309 | 0.78 | KMT2A (0.47) | LMNAMAPTKDM4EKMT2ANOTUM | |
| SCHEMBL5540279 | 0.78 | RAB9A (0.47) | LMNAMAPTKDM4EARKMT2A | |
| SCHEMBL1387640 | 0.78 | CYP19A1 (0.50) | LMNAMAPTKDM4ECYP1A2CYP3A4 | |
| SCHEMBL17625930 | 0.78 | ATM (0.42) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 119 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113912590-B | (+/-) -Marinopyrole A derivative and preparation method and application thereof | 四川大学 | 2022-11-29 | — | — | CN | claimed |
| CN-113912590-A | (+/-) -Marinopyrole A derivative and preparation method and application thereof | 四川大学 | 2022-01-11 | — | — | CN | claimed |
| US-20120101100-A1 | HETEROCYCLIC UREA DERIVATIVES AND METHODS OF USE THEREOF-211 | ASTRAZENECA AB (SE) | 2012-04-26 | — | — | US | claimed |
| WO-2011049274-A1 | IMIDAZOLE DERIVATIVES AND COMPOSITIONS FOR TREATING MELANOMA | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2011-04-28 | — | — | WO | claimed |
| CN-102015699-A | Heterocyclic urea derivatives and methods of use thereof-211 | ASTRAZENECA AB | 2011-04-13 | — | — | CN | claimed |
| EP-1441719-B1 | N-SUBSTITUTED PYRROLIDIN DERIVATIVES AS DIPEPTIDYL PEPTIDASE IV INHIBITORS | HOFFMANN LA ROCHE (CH) | 2011-03-30 | — | — | EP | claimed |
| EP-2262801-A1 | HETEROCYCLIC UREA DERIVATIVES AND METHODS OF USE THEREOF-211 | AstraZeneca AB (SE) | 2010-12-22 | — | — | EP | claimed |
| US-7803819-B2 | DPP IV inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2010-09-28 | — | — | US | claimed |
| CN-1713907-B | N-substituted pyrrolidine derivatives as dipeptidyl peptidase IV inhibitors | HOFFMANN LA ROCHE | 2010-05-26 | — | — | CN | claimed |
| WO-2009106885-A1 | HETEROCYCLIC UREA DERIVATIVES AND METHODS OF USE THEREOF-211 | ASTRAZENECA AB (SE) | 2009-09-03 | — | — | WO | claimed |
| US-20070259925-A1 | DPP IV INHIBITORS | BOEHRINGER MARKUS | 2007-11-08 | — | — | US | claimed |
| CN-1829721-A | Spiro '1-azabicyclo' 2.2.2! octan-3,5'-oxazolidin - 2'-one! derivatives with affinity to the alpha7 nicotinic acetylcholine receptor | ASTRAZENECA AB (SE) | 2006-09-06 | — | — | CN | claimed |
| CN-1713907-A | N-substituted pyrrolidine derivatives as dipeptidyl peptidase IV inhibitors | HOFFMANN LA ROCHE (CH) | 2005-12-28 | — | — | CN | claimed |
| US-20050096348-A1 | DPP IV inhibitors | BOEHRINGER MARKUS (CH) | 2005-05-05 | — | — | US | claimed |
| EP-1441719-A1 | N-SUBSTITUTED PYRROLIDIN DERIVATIVES AS DIPEPTIDYL PEPTIDASE IV INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2004-08-04 | — | — | EP | claimed |
| US-20030130281-A1 | DPP IV inhibitors | HOFFMAN-LA ROCHE INC. | 2003-07-10 | — | — | US | claimed |
| WO-2003037327-A1 | N-SUBSTITUTED PYRROLIDIN DERIVATIVES AS DIPEPTIDYL PEPTIDASE IV INHIBITORS | F. HOFFMANN-LA-ROCHE AG (CH) | 2003-05-08 | — | — | WO | claimed |
| US-20230174533-A1 | PURINE DIONES AS WNT PATHWAY MODULATORS | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2023-06-08 | — | — | US | disclosed |
| WO-2001049288-A9 | NOVEL COMPOUNDS AND COMPOSITIONS AS PROTEASE INHIBITORS | MERCK FROSST CANADA INC (CA) | 2001-10-25 | — | — | WO | disclosed |
| WO-2001049288-A1 | NOVEL COMPOUNDS AND COMPOSITIONS AS PROTEASE INHIBITORS | MERCK FROSST CANADA & CO. (CA) | 2001-07-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230174533-A1 | PURINE DIONES AS WNT PATHWAY MODULATORS | WNT1, WNT3A, WNT3 | LMNA 2103/4885MAPT 4782/4885IDO1 541/4885 |
| US-20070259925-A1 | DPP IV INHIBITORS | DPP4, DPP3, DPP7 | LMNA 4657/4885MAPT 3608/4885IDO1 1525/4885 |
| US-20120101100-A1 | HETEROCYCLIC UREA DERIVATIVES AND METHODS OF USE THEREOF-211 | UROD, UMPS, SLC14A1 | LMNA 2441/4885MAPT 2015/4885IDO1 1081/4885 |
| US-20030130281-A1 | DPP IV inhibitors | DPP4, DPP3, DPP7 | LMNA 4737/4885MAPT 4020/4885IDO1 623/4885 |
| US-20050096348-A1 | DPP IV inhibitors | DPP4, DPP3, DPP7 | LMNA 4657/4885MAPT 3608/4885IDO1 1525/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.